Breaking News
Get 40% Off 0
🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For Free Copy Portfolio
Close

Ascletis Pharma Inc (1672)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.21 -0.01    -0.82%
31/05 - Closed. Currency in HKD ( Disclaimer )
  • Volume: 702,000
  • Bid/Ask: 1.21 / 1.22
  • Day's Range: 1.21 - 1.26
Type:  Equity
Market:  Hong Kong
ISIN:  KYG0520K1094 
Ascletis Pharma 1.21 -0.01 -0.82%

Ascletis Pharma Company Profile

 
Read the Ascletis Pharma Inc company profile to learn more about the business and the management team. View Ascletis Pharma Inc facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

219

Equity Type

ORD

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People’s Republic of China.

Contact Information

Address Building D 12th Floor
198 Qidi Road, HIPARK Xiaoshan District Hangzhou,311200
China
Phone 86 571 8538 9730
Fax 86 571 8538 9730

Top Executives

Name Age Since Title
Jinzi Jason Wu 60 2013 Founder, Chairman & CEO
Yizhen Wei 49 2018 Independent Non-Executive Director
Hejingdao Wu 50 2018 Senior VP of Operations & Executive Director
Lin Hua 50 2018 Independent Non-Executive Director
Jiong Gu 52 2018 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1672 Price Commentary

Write your thoughts about Ascletis Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email